Two Cases of Mnckeberg's Medial Sclerosis on the Face

Monckeberg's medial sclerosis is a degenerative process related to age, and is particularly associated with long-standing diabetes mellitus. The media of small and medium-sized muscular arteries are usually involved. Although its pathogenesis is still unknown, its presence can predict the risk of cardiovascular events and leg amputation in diabetic patients. In our two cases, Mnckeberg's medial sclerosis was shown as a bean-sized, pulsatile mass which occurred from an inferior labial branch of the facial artery. Neither paient had a history of diabetes mellitus or calcification in any part of the body, nor an abnormality with their calcium metabolism. Herein, we report a case of a man and a woman with Mnckeberg's medial sclerosis. This condition is so rare that it has not been reported in the Korean dermatologic literature before. Moreover, Mckeberg's medial sclerosis is very rarely found without diabetes mellitus.

A Case of Pyoderma-Pyostomatitis Vegetans / 대한피부과학회지

Pyoderma-pyostomatitis vegetans (PD-PSV) is a rare, benign, eosinophilic pustular and vegetating mucocutaneous disease characterized by skin lesions which typically involve the axillary and genital regions, the face and the scalp. PD-PSV was at first regarded as a subtype of bullous disease. However, due to the lack of abnormality under a immunofluorescent microscope, it could be diffentiated from bullous disease. A 48-year woman presented with a 6-month history of sharply-outlined, exudative, papillomatous and vesiculopustular vegetating plaques on the perioral, umbilicus and nasal mucosa, tips of her fingers and toes and perianal region. A skin biopsy taken from the lip and umbilicus showed papillary dermal edema and focal inflammatory cell infiltration composed of many eosinophils, intraepithelial microabscesses, focal spongiosis, and exocytosis. No abnormalities were found during an immunofluorescence study. The lesions were almost cleared with 20 mg of triamcinolone and 200 mg of cyclosporin medication during a 3-month treatment period.